Guía OncoSur de Cáncer de mama 88 > BIBLIOGRAFÍA 1. Eggersmann TK, Degenhardt T, Gluz O, Wuerstlein R, Harbeck N. CDK4/6 Inhibitors Expand the Therapeutic Options in Breast Cancer: Palbociclib, Ribociclib and Abemaciclib. Bio Drugs. 2019;33(2):125-35. 2. Cardoso F, Senkus E, Costa A, Papadopoulos E, Aapro M, André F, et al. 4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer. Ann Oncol. 2018;1;29(8):1634-57. 3. Chacón López‑Muñiz JI, de la Cruz Merino L, Gavilá Gregori J, Martínez Dueñas E, Oliveira M, Seguí Palmer MA, et al. SEOM clinical guidelines in advanced and recurrent breast cancer (2018). Clin Transl Oncol. 2019;21:31-45. 4. Robertson JF, Bondarenko IM, Trishkina E, Dvorkin M, Panasci L, Manikhas A, et al. Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial. Lancet. 2016;388(10063):2997. 5. Finn RS, Martin M, Rugo HS, Jones S, Im SA, Gelmon K, et al. Palbociclib and Letrozole in Advanced Breast Cancer. N Engl J Med. 2016;375(20):1925. 6. Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, et al. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. Ann Oncol. 2018;29(7):1541. 7. Johnston S, Martin M, Di Leo A, Im SA, Awada A, Forrester T, et al. MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer. NPJ Breast Cancer. 2019;5:5. 8. Slamon DJ, Neven P, Chia S,Fasching PA, De Laurentis M, Im S-A, et al. Overall survival (OS) results of the phase III MONALEESA-3 trial of postmenopausal patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor 2-negative (HER2-) advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib (RIB). ESMO 2019 Congress; 29 September 2019. Available from: https://oncologypro.esmo.org/ Meeting-Resources/ESMO-2019-Congress/Overall-survival-OS-results-of-the-Phase-III-MONALEESA-3trial-of-postmenopausal-patients-pts-with-hormone-receptor-positive-HR-human-epidermal-growth-factor-2negative-HER2-advanced-breast-cancer-ABC-treated-with-fulvestrant-FUL-ribocicl 9. Slamon DJ, Neven P, Chia S, Fasching PA, De Laurentiis M, Im SA, et al. Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3. J Clin Oncol. 2018;36(24):2465. 10. Sledge GW, Toi M, Neven P, et al. The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2A Randomized Clinical Trial. JAMA Oncol. Published online September 29, 2019. DOI: https://doi.org/10.1001/ jamaoncol.2019.4782 Figura 3. Algoritmo de secuencia de quimioterapia. Opciones de quimioterapia Antraciclinas y taxanos previos Preferencias del paciente (según perfil de toxicidad) Antraciclinas Taxanos Capecitabina Eribulina Vinorelbina Gemcitabina Sales de platino Antraciclinas previas Taxanos previos Taxanos Antraciclinas
RkJQdWJsaXNoZXIy MTQzMjMwMg==